IDiyas

For the Inventor, By the Inventor

Saitama-ken, Japan

Noriyoshi Sueda

USPTO Granted Patents = 12

Average Co-Inventor Count = 6.0

ph-index = 5

Forward Citations = 189(Granted Patents)


Location History:

  • Tokyo, JA (1977 - 1978)
  • Kawagoe, JP (1985 - 1987)
  • Saitama, JP (1989 - 1992)
  • Ohimachi, JP (1996)
  • Saitama-ken, JP (1997 - 1998)

Company Filing History:

goldMedal12 out of 200 
 
Nisshin Flour Milling Co., Ltd.
 patents

Years Active: 1977-1998

Loading Chart...
12 patents (USPTO):Explore Patents
1. 5847123 - Imide derivatives for inhibiting the production of interleukin-1.beta. (1998-12-08),
2. 5621010 - Urea derivatives and their use as ACAT inhibitors (1997-04-15),
3. 5576335 - Urea derivatives and their use as ACAT inhibitors (1996-11-19),
4. 5116855 - Rhodanine derivatives and pharmaceutical compositions (1992-05-26),
5. 4886803 - Benzimidazole derivatives (1989-12-12),
6. 4659833 - Optically active isocarbostyril derivatives and a method of preparing (1987-04-21),
7. 4526893 - Isocarbostyril derivatives (1985-07-02),
8. 4521339 - Ansatrienols (1985-06-04),
9. 4096338 - Butenoic and pyruvic acid derivatives (1978-06-20),
10. 4042617 - Process for preparing a 2-methyl-(substituted aryl)-pyruvic acid compound (1977-08-16),
11. 4016196 - Butenoic and pyruvic acid derivatives (1977-04-05),
12. 4007217 - Process for producing 2-hydroxy-3-butenoic acid derivatives (1977-02-08),

Title: The Innovative Mind of Noriyoshi Sueda

Introduction

Noriyoshi Sueda, located in Saitama-ken, Japan, is a prominent inventor known for his contributions to the field of pharmaceuticals. With an impressive portfolio of 12 patents, Sueda has dedicated his career to the development of innovative compounds aimed at treating various medical conditions.

Latest Patents

Sueda's recent patents reflect his ongoing commitment to addressing critical health challenges. One notable invention is related to imide derivatives that inhibit the production of interleukin-1 beta (IL-1β). These imide compounds, particularly those with a propioloyl group or pharmaceutically acceptable salts, show remarkable promise in preventing IL-1β and Tumor Necrosis Factor alpha (TNF-α), which are involved in diseases such as chronic rheumatism, sepsis, ulcerative colitis, and Crohn's disease.

Additionally, Sueda has developed urea derivatives that serve as ACAT (Acyl-CoA: Cholesterol Acyltransferase) inhibitors. These derivatives exhibit both ACAT inhibitory and antioxidative activities, making them valuable for the prophylaxis and treatment of hypercholesterolemia and atherosclerosis.

Career Highlights

Sueda’s career has been marked by a focused approach toward pharmaceutical innovation. His work at Nisshin Flour Milling Co., Ltd. has allowed him to engage in significant research and development activities. This company is well-respected in Japan and provides a platform for Sueda to explore and develop groundbreaking medicinal compounds.

Collaborations

During his career, Sueda has collaborated with talented individuals such as Katsura Kogure and Sizuo Himoto. These collaborations have facilitated the exchange of ideas and expertise, contributing to the successful development and patenting of novel compounds.

Conclusion

Noriyoshi Sueda exemplifies the essence of innovation in the pharmaceutical sector. With a robust list of patents and a commitment to addressing pressing health issues, Sueda continues to impact the medical field significantly. His innovative compounds may hold the key to better treatments for numerous diseases, showcasing the vital role of inventors in medical advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…